Pular para o conteúdo principal
Ranking Invest

CCCC - C4 Therapeutics, Inc.

Segmento: HealthcareC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Análise Ranking Invest

Valor de Mercado
$ 394.91 Mi
IVR
-0.43Índice proprietário de comparação relativa: -0,43.
IVR2
-1.07Leitura proprietária complementar: -107%.
MLL
-1.07Leitura proprietária complementar: -107%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 247.26 Mi

Dívida Líquida

-$ 78.61 Mi

L4T

-$ 106.95 Mi

MM4T

-363.35%

Indicadores Básicos

ROE

-43.25%

Índices de Previsibilidade

Receita Líquida

F0.46

Lucro

A0.13

Margem

C0.47

Índices de Tendência

Receita Líquida

D0.99

Lucro

B5.17

Margem

B4.60

Índices de Endividamento

DIV/PAT

-0.32

DIV/L4T

0.74

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.